4d Pharma PLC Annual Report and Notice of AGM (3674A)
28 Maggio 2019 - 3:50PM
UK Regulatory
TIDMDDDD
RNS Number : 3674A
4d Pharma PLC
28 May 2019
4D pharma plc
(the "Company" or "4D")
Annual Report and Notice of AGM
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutics, announces that the Annual
Report and Accounts for the year to 31 December 2018 and Notice of
the Company's Annual General Meeting ("AGM") have been posted to
shareholders.
An electronic copy of each of the Annual Report and Accounts and
the Notice of AGM is available on the Company's website,
www.4dpharmaplc.com.
The AGM will be held in the Chicago Room, Sofitel, Terminal 5,
Wentworth Drive, London Heathrow Airport, Hounslow TW6 2GD, at 10
a.m. on Thursday 20 June 2019.
For further information please contact:
4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130
Fay Weston, Head of Investor Relations + 44 (0)7990 381713
Zeus Capital Limited - Nomad and Joint Broker +44 (0) 161 831 1512
Dan Bate / Jordan Warburton
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform that rationally identifies novel bacteria
based on a deep understanding of function and mechanism. 4D's Live
Biotherapeutic products are orally delivered single strains of
bacteria that are naturally found in the healthy human gut. 4D has
three clinical studies in progress, namely a Phase II clinical
study of Blautix(R) in Irritable Bowel Syndrome, a Phase I/II study
of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid
tumours and a Phase I study of MRx0518 in a neoadjuvant setting for
patients with solid tumours. Other focus programmes include disease
areas such as asthma and CNS disease.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSLLFSVETITFIA
(END) Dow Jones Newswires
May 28, 2019 09:50 ET (13:50 GMT)
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2023 a Apr 2024
